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Cynomolgus monkeyVariable region 1 (V1) of the SPRY domain of TRIM5α is a major determinant for species-speciﬁc virus
restriction in primates. We previously reported that a chimeric TRIM5α containing baboon V1 in the
background of cynomolgus monkey TRIM5α showed potent anti-human immunodeﬁciency virus type 2
(HIV-2) activity. Since baboons are reportedly sensitive to HIV-2 infection, there was a discrepancy between
the ability of baboon TRIM5α V1 to restrict HIV-2 and baboon sensitivity to HIV-2. In the study presented
here, we examined the roles of V2 and V3 of the baboon TRIM5α SPRY domain in its anti-HIV-2 activity. A
chimeric TRIM5α containing the entire baboon SPRY domain showed weak anti-HIV-2 activity. This
attenuation of activity was caused by a single serine-to-proline substitution in baboon TRIM5α V2. These
ﬁndings indicate that the combination of V1 with other variable regions of SPRY is important in anti-HIV-2
activity of primate TRIM5α.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) has a very narrow
host range limited to humans, chimpanzees, gibbons, and pig-tailed
monkeys in vivo (Lusso et al., 1988; Arthur et al., 1989; Agy et al., 1992),
and gorillas in vitro (Locher et al., 1996). Previous experiments have
demonstrated that Old World monkeys (OWM) such as rhesus and
cynomolgusmonkeys are not sensitive to HIV-1 infection. This block is
partly explained by the presence of tripartite motif 5α (TRIM5α)
(Stremlau et al., 2004) in cells of those monkeys. Rhesus and
cynomolgus monkey TRIM5α restricts HIV-1 infection but not simian
immunodeﬁciency virus isolated frommacaque (SIVmac) (Stremlau et
al., 2004; Nakayama et al., 2005). In contrast, human TRIM5α fails to
restrict those viruses, but potently restricts N-tropic murine leukemia
viruses (N-MLV) (Hatziioannou et al., 2004; Kecksova et al., 2004; Yap
et al., 2004). Unlike human and other OWM, pig-tailed monkeys lack
expression of TRIM5α, whereas express TRIM5θ and TRIM5η lacking
anti-HIV-1 activity (Brennan et al., 2007). TRIM5α shares with other
splicing variants a common amino-terminal TRIM motif, comprising
RING, B-box and coiled-coil domains (which is called RBCC domain),
and encodes a unique SPRY (B30.2) domain (Reymond et al., 2001).
Studies on recombinant TRIM5αs between human and rhesusmonkey
have shown that the determinant of the species speciﬁcity resides in
the SPRY domain (Perez-Caballero et al., 2005; Sawyer et al., 2005).
Studies on recombinant TRIM5αs between African green monkeyayama).
ll rights reserved.(AGM) and cynomolgus monkey demonstrated that 17-amino acid
residues and adjacent AGM-speciﬁc 20-amino acid duplication in the
SPRY domain determined species-speciﬁc restriction of SIVmac
(Nakayama et al., 2005). Similarly, a study comparing orangutan and
gorilla TRIM5α also showed that the amino acid residues at the 385th
and 389th positions in the SPRY domain of orangutan TRIM5α are
important for inhibiting HIV-1 and SIVmac (Ohkura et al., 2006).
Furthermore, by comparing human and rhesus monkey TRIM5α
restriction of N-MLV, the amino acid residues of human TRIM5α at
the 409th and 410th positions in the SPRY domain are found to be
important for inhibiting N-MLV (Peron et al., 2006). Interestingly, a
study comparing human and rhesus monkey TRIM5α showed that a
single arginine to proline (P) change at the 332nd position in the SPRY
domain of humanTRIM5α conferredpotent restriction of not onlyHIV-
1 but also SIVmac239 (Stremlau et al., 2005; Yap et al., 2005).
Human immunodeﬁciency virus type 2 (HIV-2) has a genome
similar to that of SIVmac (Hahn et al., 2000), which is not restricted by
rhesus monkey and cynomolgus monkey TRIM5α. We previously
evaluated the ability of cynomolgus monkey TRIM5α to restrict eight
different HIV-2 isolates and found that it could restrict viruses carrying
P at the 119th or 120th position of the capsid protein (CA), whereas it
failed to restrict those with either alanine or glutamine (Song et al.,
2007). HIV-2 GH123 strain has P at the 120th position of CA and was
restricted by cynomolgus monkey TRIM5α while its mutant HIV-2
GH123/Q carrying glutamine was not restricted. Subsequently, we
found that rhesus monkey TRIM5α showed broad spectrum of HIV-2
restriction and could restrict HIV-2 strains that were not restricted by
cynomolgusmonkey TRIM5α (Kono et al., 2008). The variable region 1
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determinant for this restriction, since a chimeric TRIM5α containing
cynomolgus monkey V1 in the background of rhesus monkey TRIM5α
could not restrict HIV-2 GH123/Q, while a chimeric TRIM5α contain-
ing rhesus monkey V1 in the background of cynomolgus monkey
could (Kono et al., 2008). On the other hand, we found that a
chimeric TRIM5α containing baboon V1 in the background of
cynomolgus monkey TRIM5α could restrict both HIV-2 GH123 and
HIV-2 GH123/Q, despite the fact that baboons are sensitive to HIV-2
infection (Barnett et al., 1994; Locher et al., 1998, 2001). One possible
explanation for this discrepancy is that variable region 2 or 3 (V2 or
V3) of SPRY domain also contributes to anti-HIV-2 activity. In the
study presented here, we examined the contribution of V2 and V3 of
baboon TRIM5α SPRY domain to anti-HIV-2 activity and found that a
single amino acid in V2 affects its restriction activity against HIV-2.
Results
Variable region 2 (V2) of baboon TRIM5α SPRY (B30.2) domain weakens
anti-HIV-2 activity
In our previous study, we constructed a recombinant Sendai virus
(SeV) expressing chimeric TRIM5α between cynomolgus monkeyFig. 1. Alignments of amino acid sequence of cynomolgus monkey (CM), rhesus monkey (R
indicated by labeled bars over the sequences. Variable regions 1, 2, and 3 are indicated by a
enzyme site, respectively. Dots denote the amino acid residues identical to one of the cynomo
rhesus monkey and baboon TRIM5αs. The box marks the amino acid residue that affects anTRIM5α and baboon TRIM5α by using Sph I and BamH I restriction
enzyme digestion. As can be seen in Fig. 1, the N-terminal fragment
contains RING, B-box2, and coiled-coil domains, the central fragment
contains V1 of the SPRY domain, and the C-terminal fragment contains
V2 and V3 of the SPRY domains. In that study, we reported a chimeric
TRIM5α containing baboon V1 in the background of cynomolgus
monkey (2B2, but renamed CBC in this study) (Fig. 2A) could restrict
HIV-2 GH123/Q, which was not restricted by cynomolgus monkey
TRIM5α. To examine anti-HIV-2 activity of TRIM5α containing the
entire baboon SPRY domain, we constructed a recombinant SeV
expressing a chimeric TRIM5α containing V1, V2, and V3 of the SPRY
domain of baboon TRIM5α (CBB) (Fig. 2A). Western blot analysis
using an antibody against hemagglutinin (HA) tag showed that CBB
chimeric TRIM5α was expressed in recombinant SeV infected human
T-cell line MT4 cells at levels similar to those of rhesus and
cynomolgus monkey TRIM5αs and CBC chimeric TRIM5α (Fig. 2B).
Those TRIM5αs were tested for their ability to restrict X4-tropic HIV-1
strain NL43 and HIV-2 strains GH123 and GH123/Q.MT4 cells infected
with recombinant SeV expressing each of the TRIM5αs were then
superinfected with HIV-1 NL43, HIV-2 GH123, or HIV-2 GH123/Q. We
used SeV expressing cynomolgus monkey TRIM5α lacking the SPRY
domain, CM SPRY(−) TRIM5α, as a negative control for functional
TRIM5α. Both CBC and CBB chimeric TRIM5αs as well as rhesush), and baboon TRIM5αs. The RING, B-box2, coiled-coil and SPRY (B30.2) domains are
broken bar over the sequence. Inverted triangles denote Sph I and BamH I restriction
lgus monkey TRIM5αs and dashes denote a lack of amino acid residue that is present in
ti-HIV-2 activity of TRIM5α (see Results).
Fig. 2. (A) Schematic representation of chimeric and mutant TRIM5αs, and summary of the results. White and grey bars denote rhesus monkey (Rh) and cynomolgus monkey (CM)
sequences, respectively. B denotes a baboon sequence. The amino acid at the 385th or 383rd position in V2 of the SPRY domain is indicated in the construct. +++, ++, +, and−
denote more than 1000-fold, 100- to 1000-fold, 8- to 100-fold, and less than 8-fold suppression of virus growth, respectively, compared with the negative control on day 6. ⁎ denotes
that anti-HIV-2 activity is slightlyweaker than that of wild type CM TRIM5α. ⁎⁎ denotes that anti-HIV-2 GH123/Q activity of 2B2 (CBC) TRIM5αwas assigned as+++ in our previous
report (Kono et al., 2008), but it was assigned as ++ in the present study. Because the CBC TRIM5α suppressed HIV-2 GH123/Q approximately 1000-fold, a slight difference among
experiments caused ﬂuctuation of assignment. However, the order of anti-HIV-2 GH123/Q activity is fairly constant among different experiments (rhesusmonkey TRIM5α is themost
potent and CBC is the next). (B) Twenty-four hours after Sendai virus (SeV) infection, TRIM5α protein in lysates of MT4 cells infected with recombinant SeV expressing 111 (Rh), 222
(CM), 2B2 (CBC), CBB, CBB P385S, Rh S385P, or CM S383P TRIM5α were visualized by Western blotting with an antibody against HA tag.
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restricted HIV-1 NL43 (data not shown) and HIV-2 GH123 (Fig. 3A
left). In the case of HIV-2 GH123/Q (Fig. 3A right), rhesus monkey
TRIM5α but not cynomolgus monkey TRIM5α restricted the virus
growth as previously described (Kono et al., 2008). HIV-2 GH123/Q
was restricted potently by CBC chimeric TRIM5α, although the virus
grew at higher titer than in cells expressing rhesus monkey TRIM5α
(pb0.0005, t-test, n=8), conﬁrming the importance of V1 sequence
of rhesus monkey TRIM5α to restrict HIV-2 GH123/Q (Kono et al.,
2008). On the other hand, this virus was only moderately restricted by
CBB chimeric TRIM5α, since the virus attained clearly higher titers in
cells expressing CBB chimeric TRIM5α than in those expressing CBC
chimeric TRIM5α (pb0.0005, t-test, n=6). This indicates that theFig. 3. (A) MT4 cells were infected with recombinant SeV expressing CBC (▪), CBB (□), 111
recombinant SeV expressing CBC (▪), RBR (Δ), 111 (Rh) (●), 222 (CM) (○), or CM SPRY(−)
(□), CBB P385S (●), or CM SPRY(−) (*) TRIM5α. (D) MT4 cells were infected with recombi
TRIM5α. Nine hours after infection, cells were superinfected with HIV-2 GH123 (A–D, left) o
levels of p25 from HIV-2. Error bars show actual ﬂuctuations between levels of p25 in duplianti-HIV-2 GH123/Q activity of CBB chimeric TRIM5α was weaker
than that of CBC chimeric TRIM5α.
We further observed that rhesus monkey chimeric TRIM5α
containing baboon V1 (RBR) restricted HIV-2 GH123/Q replication
to the same extent as CBC chimeric TRIM5α did (Fig. 3B right). The
difference between CBB and RBR chimeric TRIM5αs in the SPRY
domain was detected only at the 385th amino acid residue in V2,
where baboon TRIM5α carries P and rhesus monkey TRIM5α carries
serine (S) (Fig.1 box). CBC chimeric TRIM5α also carries S at the 385th
position. These results thus strongly suggest that the amino acid
residue at the 385th position of TRIM5α affects its restriction activity
against HIV-2 GH123/Q infection. To conﬁrm this hypothesis, we also
constructed an SeV expressing mutant CBB TRIM5α in which amino(Rh) (●), 222 (CM) (○), or CM SPRY(−) (*) TRIM5α. (B) MT4 cells were infected with
(*) TRIM5α. (C) MT4 cells were infected with recombinant SeV expressing CBC (▪), CBB
nant SeV expressing Rh (▪), Rh S385P (□), CM (●), CM S383P (○), or CM SPRY(−) (*)
r HIV-2 GH123/Q viruses (A–D, right). Culture supernatants were separately assayed for
cate samples. A representative of two or three independent experiments is shown.
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Fig. 4. (A) TRIM5α protein lysates of MT4 and CEM-SS cells infected with recombinant SeV expressing CBC, CBB, 111 (Rh), or 222 (CM) were visualized by Western blotting with
antibodies against HA tag and actin. The relative TRIM5α expression obtained from the band intensity of TRIM5α divided by that of actin is shown. (B) CEM-SS cells were infected
with recombinant SeV expressing CBC (▪), CBB (□), 111 (Rh) (●), 222 (CM) (○), or CM SPRY(−) (*) TRIM5α. Nine hours after infection, cells were superinfected with HIV-2 GH123,
or HIV-2 GH123/Q viruses. Culture supernatants were separately assayed for levels of p25. Error bars show actual ﬂuctuations between levels of p25 in duplicate samples. A
representative of three independent experiments is shown.
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TRIM5α; Fig. 2A) and compared its ability to restrict HIV-2 GH123/Q
with that of CBB TRIM5α. As expected, CBB P385S TRIM5α could
inhibit HIV-2 GH123/Q replication to a larger extent than CBB
chimeric TRIM5α did (Fig. 3C right) (pb0.00005, t-test, n=4). This
ﬁnding shows that a single amino acid substitution from P to S at
the 385th position of baboon TRIM5α strengthens its anti-HIV-2
activity.
A. single amino acid in V2 of the SPRY domain of TRIM5α affects its
restriction activity against HIV-2
Cynomolgus monkey TRIM5α has S at the 383rd amino acid
position, which corresponds to the 385th amino acid of baboon and
rhesus monkey TRIM5αs (Fig. 1 box). To know whether an S-to-P
amino acid substitution at the 385th or 383rd position also affects
anti-HIV-2 activity of rhesus or cynomolgus monkey TRIM5α, we
constructed SeVs expressing mutant rhesus monkey TRIM5α with
amino acid residue S at the 385th position replaced with P (Rh S385P
TRIM5α) and mutant cynomolgus monkey TRIM5α with S at the
383rd position replaced with P (CM S383P TRIM5α) (Fig. 2A). These
mutant TRIM5αs were expressed at levels similar to those of the wild
type TRIM5α (Fig. 2B). CM S383P TRIM5α and the wild type
cynomolgus monkey TRIM5α restricted HIV-2 GH123 replication
(Fig. 3D left), whereas they failed to restrict HIV-2 GH123/Q
replication (Fig. 3D right). However, it should be noted that HIV-2GH123 attained slightly higher titers on day 6 in cells expressing CM
S383P TRIM5α than in those expressing the wild type cynomolgus
monkey TRIM5α (Fig. 3D left). The difference was very small, but
statistically signiﬁcant in six independent samples (pb0.0001, t-test).
In contrast, we could not detect any statistically signiﬁcant differences
in anti-HIV-2 activity between the wild type and mutant rhesus
monkey TRIM5αs in six independent samples (Fig. 3D). It is possible
that the effects of small amino acid changes in V2 on anti-viral activity
vary depending on differences in V1.
Chimeric TRIM5α containing the baboon SPRY domain failed to restrict
HIV-2 GH123/Q replication in human T cell line CEM-SS
After we obtained data presented in Fig. 3, we realized that the
expression levels of TRIM5α protein by SeVs are much lower in another
T cell line CEM-SS than those in MT4 cells. To examine the restriction
ability of chimeric TRIM5αs with more physiological levels of expres-
sion, we repeated the experiment of Fig. 3A in CEM-SS cells. The
expression levels of TRIM5α compared to those of actin protein in CEM-
SS cells were approximately one-ﬁfth of those in MT4 cells (Fig. 4A). As
shown in Fig. 4B, all TRIM5αs inhibited HIV-2 GH123 replication,
although the extent of inhibition varied among the TRIM5αs. CBB
chimeric TRIM5α partially inhibited HIV-2 GH123 (Fig. 4B left) but
failed to inhibit HIV-2 GH123/Q (Fig. 4 B right) in CEM-SS cells. These
ﬁndings demonstrate that chimeric TRIM5α containing the baboon
SPRY domain fails to restrict HIV-2 GH123/Q replication.
Fig. 5. (A) TRIM5α protein lysates of CEM-SS cells infected with recombinant SeV expressing BBB, BBB P385S, CBB, or CBB P385S TRIM5α were visualized by Western blotting with
antibodies against HA tag and actin. (B) CEM-SS cells were infectedwith recombinant SeV expressing BBB (□), BBB P385S (▪), CBB (○), CBB P385S (●),111 (Rh) (⋄), CM SPRY(−) (*), or
AGM TRIM5α lacking coiled-coil domain (CC(−) TRIM5α) (Δ). Nine hours after infection, cells were superinfected with HIV-2 GH123, or HIV-2 GH123/Q viruses. Culture supernatants
were separately assayed for levels of p25. Error bars show actual ﬂuctuations between levels of p25 in duplicate samples. A representative of two independent experiments is shown.
Fig. 6. Structural model of the SPRY domain of baboon TRIM5α. The 3-D model of the
baboon SPRY domain was constructed with a homology-modeling technique using
Modeller 9v4, and visualized with PyMol v1.0r2. The baboon SPRY model (green
cartoon) is superimposed on the structure of the SPRY domain of mouse TRIM21
(orange backbone trace). Insertions in the baboon SPRY domain relative to the
templates are shown in red, and V1, V2 and V3 in blue. The spheres indicate P at the
385th position in V2.
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replication in CEM-SS cells
Finally, we constructed SeV expressing the full-length baboon
TRIM5α (BBB TRIM5α), and the mutant baboon TRIM5α in which
amino acid residue P at the 385th position was replaced with S (BBB
P385S TRIM5α) to conﬁrm the effect of the 385th amino acid in the
full-length baboon TRIM5α. Expression levels of BBB and BBB P385S
TRIM5αs were comparable to those of CBB and CBB P385S TRIM5αs
(Fig. 5A). Consistent with results presented in Fig. 4B, BBB TRIM5α
restricted HIV-2 GH123 (Fig. 5B left), but failed to restrict HIV-2
GH123/Q (Fig. 5B right) in CEM-SS cells. Anti-HIV-2 GH123 and
GH123/Q activities of BBB and BBB P385S TRIM5αs were comparable
to those of CBB and CBB P385S TRIM5αs, respectively (Fig. 5B). These
results excluded the possibility that the RBCC domain of baboon
TRIM5α contains potency determinants for restriction of HIV-2.
Furthermore, the difference in anti-HIV-2 GH123 and GH123/Q
activity between BBB and BBB P385S TRIM5α was also observed in
CEM-SS cells (Fig. 5B right) (pb0.01, n=4, t-test) and MT4 cells (data
not shown) conﬁrming that a single amino acid at the 385thposition of
the baboon TRIM5α affects its restriction activity against HIV-2. In Fig.
5B, therewas no difference in the effects of HIV-2GH123 andGH123/Q
replication between CM SPRY(−) TRIM5α and AGM TRIM5α lacking
coiled-coil domain (CC(−)TRIM5α). CM SPRY(−) TRIM5α sup-
pressed activity of endogenous TRIM5α, while CC(−) TRIM5α was a
non-interferingmutant (Nakayama et al., 2006;Maegawa et al., 2008).
Therefore, these results indicated that effects of endogenous TRIM5α
in CEM-SS cells could be neglected in our assay.
Structural model of the SPRY domain of baboon TRIM5α
To gain further insight into the structural effects of single amino
acid substitution at the 385th position of the baboon SPRY domain, a
three-dimensional (3-D) model of the baboon SPRY domain was
constructed by a homology-modeling based on the recently publishedcrystal structure of the PRYSPRY domain of mouse TRIM21 (protein
data bank (PDB) ID: 2VOK and 2VOL) (Keeble et al., 2008) and the
human PRYSPRY-19q13.4.1 domain (PDB ID: 2FBE) (Gruetter et al.,
2006). A previous study described the 3-D model of the SPRY domain
of TRIM5α based on the structure of the GUSTAVUS SPRY domain
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between the two more recently published SPRY domain structures
(2VOK and 2VOL) and the SPRY domain of baboon TRIM5α is 35% and
is over 10% larger than the domain identity with the templates used in
the previous studies. Thus, owing to the use of more similar templates,
we expect our model to be more reliable. In our model (Fig. 6), V1 and
V2 are located in the loops at the surface of the SPRY domain structure.
Unfortunately, P residue at the 385th position in V2 was one of the
four amino acid insertions of the baboon SPRY domain sequence as
compared to the templates. However, as the insertion is short, we do
not expectmajor errors in this region of themodel, andwe can assume
that the insertion is located at the protein surface. In the model, V2 is
located near V1, and P residue at the 385th position of baboon TRIM5α
faces toward V1. It was previously speculated that V1 and V2 are
included in variable loops which form a canonical binding interface of
TRIM and other protein families with the SPRY domain (James et al.,
2007). A substitution involving P is expected to affect local backbone
conformation, and a P-to-S substitution in particular results in an
additional hydrogen bond donor–acceptor. Overall these ﬁndings
indicate that position 385 is located at a putative binding site, where a
P-to-S substitution is expected to affect the local structure and surface
chemistry. This is consistent with the observed impact of these
substitutions on TRIM5α anti-HIV-2 activity. Nevertheless, it is not yet
clear how these substitutions affect TRIM5α restriction activity and
binding afﬁnity in particular, which calls for further investigation of
the protein interactions involving TRIM5α.
Discussion
We previously reported that chimeric TRIM5α containing baboon
V1 could restrict HIV-2 GH123/Q that was not restricted by
cynomolgus monkey TRIM5α (Kono et al., 2008). Since baboons are
reportedly sensitive to HIV-2 infection, there was a discrepancy
between the ability of baboon TRIM5α V1 to restrict HIV-2 and the
susceptibility of host to virus. In the study presented here, we showed
that the anti-HIV-2 activities of full-length baboon TRIM5α and
chimeric TRIM5α containing the entire baboon SPRY domain were
weaker than that of chimeric TRIM5α containing baboon V1 alone,
and that the full-length baboon TRIM5α and chimeric TRIM5α
containing the entire baboon SPRY domain failed to restrict HIV-2
GH123/Q in CEM-SS cells. These results were consistent with those of
the previous in vivo studies (Barnett et al., 1994; Locher et al., 1998,
2001). We also found that a single amino acid in V2 of the SPRY
domain of TRIM5α affected its anti-HIV-2 activity.
There are several precedents that a single amino acid change in V1
and V3 of the SPRY domain of TRIM5α affects its restriction activity
against retroviruses (Stremlau et al., 2005; Yap et al., 2005; Peron et al.,
2006). A previous study comparing orangutan and gorilla TRIM5αs
showed that the amino acid residues at the 385th and 389th positions
(corresponding to the 389th and 393rd positions of baboon TRIM5α,
the second and third boxes, respectively, indicated by white arrows in
Fig. 7) in V2 of the SPRY domain of orangutan TRIM5α are importantFig. 7. Alignment of amino acid sequences of V2 within the SPRY domain of cynomolgus
monkey, rhesus monkey, baboon, orangutan, and gorilla TRIM5αs. The ﬁrst box
indicated by the black arrow denotes the amino acid residue that affects anti-HIV-2
activity. The second and third boxes indicated by white arrows denote the amino acid
residues that are important for anti-HIV-1 and anti-SIVmac activity of orangutan
TRIM5α.for inhibiting HIV-1 and SIVmac (Ohkura et al., 2006). Ours is the ﬁrst
report to demonstrate the importance of another amino acid residue at
the 385th (baboon) or 383rd (cynomolgus monkey) position in V2 of
the SPRY domain of TRIM5α (the ﬁrst box indicated by a black arrow in
Fig. 7) for restricting HIV-2. A structural model of the baboon TRIM5α
SPRY domain revealed that this 385th amino acid residue located near
V1, the major determinant of species-speciﬁc viral restriction of
TRIM5α. In contrast to baboon and cynomolgus monkey TRIM5αs,
there was no evidence of an obvious contribution by the 385th amino
residue for anti-HIV-2 activity in the case of rhesus monkey TRIM5α
background. It was reported that the speciﬁc combination of amino
acids in V1 and V2 plays an important role in determining speciﬁcity of
restriction (Ohkura et al., 2006). Therefore, it is possible that the
combination of amino acids inV1 andV2of the SPRYdomain of baboon
as well as cynomolgus monkey TRIM5α is more stringent in its anti-
HIV-2 activity than that of rhesus monkey TRIM5α.
We showed that anti-HIV-2 activity of CBC chimeric TRIM5α was
almost the same as that of CBB P385S TRIM5α. The amino acid
differences between CBC chimeric TRIM5α and CBB P385S TRIM5α in
the SPRY domain were located at two amino acids positions at the
389th in V2 (the second box in Fig. 7) and at the 422nd in V3 (Fig. 1).
This indicates that these amino acid substitutions did not affect the
restriction activity of TRIM5α against HIV-2, though the amino acid
substitution at the former position of gorilla TRIM5α was reported to
affect its anti-SIVmac activity (Ohkura et al., 2006). This is another
example that the effect of amino acid substitution at the speciﬁc
position in V2 could vary among different species of TRIM5α.
We observed that the CBB chimeric TRIM5α only partially inhibited
HIV-2 GH123 when we used CEM-SS cells, while it almost completely
did so when we used MT4 cells. We also found that the CBB chimeric
TRIM5α failed to inhibit HIV-2 GH123/Q when we used CEM-SS cells,
while it at least partially limited replication of HIV-2 GH123/Q when
we used MT4 cells. The anti-viral effect of TRIM5α was apparently
weaker in CEM-SS cells than inMT4 cells, whichwas at least inpart due
to lower levels of TRIM5α expression by SeV in CEM-SS cells than in
MT4 cells. The reason for these lower expression levels is not clear,
however. Since the levels of other proteins such as green ﬂuorescence
protein, TRIM22, and CCR5 expressed in CEM-SS cells by SeVwere also
low (data not shown), this is not speciﬁc to TRIM5α. We conﬁrmed
that the SeV could infect MT4 and CEM-SS cells with the same
efﬁciency (data not shown). The low levels of TRIM5α expression in
CEM-SS cells are therefore attributed to low efﬁciency in transcription
or translation of the proteins expressed by SeV.Whenwe used CEM-SS
cells, the anti-HIV-2 GH123 activity of CBB TRIM5α was weaker than
that of cynomolgus monkey TRIM5α. It is possible that baboon is
sensitive to broader strains of HIV-2 than cynomolgus monkey.
Although we have clearly demonstrated that the full-length baboon
TRIM5α cannot inhibit HIV-2 GH123/Q in CEM-SS cells, it is still
possible that genomic polymorphisms in baboon TRIM5α could affect
the sensitivity of baboons to HIV-2. In rhesusmonkey TRIM5α V1, there
is a 339th–TFP–341st to Q polymorphism, which reduces the strength
of anti-HIV-2 activity (Newman et al., 2006; Kono et al., 2008). It would
be interesting to investigate whether baboons TRIM5α have genomic
polymorphism(s), which could alter the anti-viral activity.
Materials and methods
Cloning and expression of TRIM5α
Construction of cynomolgusmonkey TRIM5α carrying an HA tag at
the C-terminus (CM-TRIM5α-HA), rhesus monkey TRIM5α carrying
an HA tag at the C-terminus (Rh-TRIM5α-HA), CBC chimeric TRIM5α
carrying an HA tag at the C-terminus (CBC chimeric TRIM5α-HA), RBR
chimeric TRIM5α carrying an HA tag at the C-terminus (RBR chimeric
TRIM5α-HA), CM SPRY(−) TRIM5α, and CC(−) TRIM5α were
described previously (Nakayama et al., 2005; Song et al., 2007; Kono
167K. Kono et al. / Virology 388 (2009) 160–168et al., 2008; Maegawa et al., 2008). To obtain the C-terminal portion of
baboon TRIM5α fused with an HA tag (BamH I to Not I), we performed
site-directed mutagenesis by using the PCR-mediated overlap primer
extension method (Ho et al., 1989). Brieﬂy, two DNA fragments with
overlapping ends were generated by using the outer primers and the
complementary primers with overlapping complementary nucleo-
tides containing the desired mutations. The resultant two fragments
were then combined in the subsequent fusion reaction to anneal the
overlapping ends. This allows the 3′ overlap of each strand to serve as a
primer for a 3′ extension of the complementary strand. Cloned RBR
chimeric TRIM5α-HA was used as a template for PCR-ampliﬁcation
with outer primers (5′-GCGGCCGCTACTATGGCTTCTGC-3′ and 5′-
GAATTCTCAAGAGCTTGGTGA-3′) and complementary primers (5′
GGCTTCCAACCTGATGCAATG-3′ and 5′-CATTGCATCAGGTTGGAAGCC-
3′) containing nucleotides speciﬁc for baboon TRIM5α (underlined).
To generate CBB chimeric TRIM5α, the previously generated C-
terminal portion of baboon TRIM5α fused with HA tag (BamH I to
Not I) and the N-terminal portion of CBC chimeric TRIM5α (Not I to
BamH I) were assembled on the pcDNA3.1 (−) vector (Invitrogen,
Carlsbad, CA). To generate CBB P385S TRIM5α, the N-terminal portion
of CBC chimeric TRIM5α (Not I to BamH I) and the C-terminal portion
of Rh-TRIM5α-HA (BamH I to Not I) were assembled on the pcDNA3.1
(−) vector.
To generate mutant rhesus monkey TRIM5α, in which an amino
acid residue S at the 385th positionwas replaced with an amino acid P
found in baboon TRIM5α (Rh S385P TRIM5α), the N-terminal portion
of rhesus monkey TRIM5α (Not I to BamH I) and the C-terminal
portion of CBB chimeric TRIM5α-HA (BamH I to Not I) were
assembled on the pcDNA3.1 (−) vector. Mutant cynomolgus monkey
TRIM5α, in which an amino acid residue S at the 383rd position was
replaced with an amino acid P (CM S383P TRIM5α), was generated by
site-directed mutagenesis with the PCR-mediated overlap primer
extension method as described above. To obtain the BamH I–Not I
fragment of CM S385P TRIM5α, cloned cynomolgus monkey TRIM5α
was used as a template for PCR-ampliﬁcation with the outer and
complementary primers speciﬁed above. The resultant fragment and
the N-terminal of cynomolgus monkey TRIM5α (Not I and Bam HI)
were assembled on the pcDNA3.1 (−) vector.
Full-length baboonTRIM5α (BBB TRIM5α)was generated by the site-
directed mutagenesis. To obtain the N-terminal portion, we performed
seven successive PCR reactions by using cloned rhesus monkey and
cynomolgus monkey TRIM5αs as templates. The primers used in these
reactions are Not-TRIM primer (5′-GCGGCCGCTACTATGGCTTCTGG-3′),
B 1 F o r p r i m e r ( 5 ′ - C C T GAG T C T G C C C T G C G G C C AC A -
GCTTCTGCCAAGCGTGCATCACTGCGAACCACAGGAAGTCCATGC-3′),
B1Rev primer (5′-GCATGGACTTCCTGTGGTTCGCAGTGATGCACGCTTGG-
CAGAAGCTGTGGCCGCAGGGCAGACTCAGG-3′), B2For primer
(5′-CCAGAAGAGGGACTGAAGGTTGATCACTGTGC-3′), B2Rev primer
(5′-GCACAGTGATCAACCTTCAGTCCCTCTTCTGG-3′), B3For primer (5′-
GAGAGAGCTCATCTCAGATCTGGAGC-3′), B3Rev primer (5′-GCTCCA-
GATCTGAGATGAGCTCTCTC-3′), and B4Rev primer (5′-GCATGC-
GAAATGTTGTTTGGAGCCAGTGTCACATCAACCCAGTAGCGTCGGA-
CATCTGTTAGC-3′) containing nucleotides speciﬁc for baboon TRIM5α
(underlined). The ﬁrst PCR reaction was performed by using rhesus
monkey TRIM5α as a template and Not-TRIM and B1Rev as primers. The
second reaction was performed by using rhesus monkey TRIM5α as a
template and B1For and B2Rev as primers. The resultant fragments were
used as templates in the third PCR reactionwith Not-TRIM and B2Rev as
primers. The forth reaction was performed by using rhesus monkey
TRIM5α as a template and B2For and B3Rev as primers. The resultant
fragmentswere used as templates in theﬁfth reactionwithNot-TRIMand
B3Rev as primers. The sixth reactionwas performed by using cynomolgus
monkey TRIM5α as a template and B3For and B4Rev as primers. The ﬁfth
and sixth fragments were used as templates in the seventh reactionwith
Not-TRIM and B4 Rev as primers. The resultant fragment and the C-
terminal of CBB TRIM5α (Sph I and Not I) were assembled on thepcDNA3.1 (−) vector. To generate mutant baboon TRIM5α (BBB P385S
TRIM5α), the N-terminal portion of BBB TRIM5α (Not I and BamH I) and
the C-terminal portion of rhesus monkey TRIM5α (BamH I and Not I)
were assembledon thepcDNA3.1 (−) vector. Theentire coding sequences
of those TRIM5αs were veriﬁed and then transferred to the Not I site of
pSeV18b+. Recombinant SeVs carrying various TRIM5αs were recovered
with a previously describedmethod (Nakayama et al., 2005). The viruses
were passaged twice in embryonated chicken eggs and used as stock for
all experiments.
Viral infection
2×105 MT4 or CEM-SS cells were infected with SeV expressing
each of the TRIM5αs at a multiplicity of infection of 10 plaque-forming
units per cell and incubated at 37 °C for 9 h. Cells were then
superinfected with 20 ng of p25 from HIV-2 GH123, or GH123/Q
strains. The culture supernatants were collected periodically, and the
level of p25 was measured with a RETROtek antigen ELISA kit
(ZeptoMetrix, Buffalo, NY).
Statistical analysis
Differences in relative p25 levels to control CM SPRY(−) TRIM5α
among chimeric TRIM5αs were evaluated by t-test.
Western blot analysis
MT4 or CEM-SS cells infected with recombinant SeVs expressing
HA tagged TRIM5αproteinswere lysed in lysis buffer (50mMTris–HCl,
pH 7.5, 150 mM NaCl, 1% Nonident P40, 0.5% sodium deoxycholate).
TRIM5α proteins in the lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Proteins in the gel were
then electronically transferred to amembrane (Immobilion; Millipore,
Billerica, MA). Blots were blocked and probed with anti-HA high
afﬁnity rat monoclonal antibody (Roche, Indianapolis, IN) and anti-
actin afﬁnity rabbit polyclonal antibody (Sigma, St. Louis, MO)
overnight at 4 °C. Blots were then incubated with peroxidase-
conjugated anti-rat IgG (American Qualex, San Clemente, CA) and
peroxidase-linked protein A (Amersham, Piscataway, NJ), and bound
antibodies were visualized with a Chemilumi-One chemiluminescent
kit (Nacalai Tesque, Kyoto, Japan).
Modeling
Three protein domain structures were used as the templates for
building the model: SPRY domains 2VOK and 2VOL of mouse TRIM21
(Keeble et al., 2008) and the human PRYSPRY domain 2FBE (Gruetter
et al., 2006). To adjust the alignment for the variable positions of the
TRIM5α SPRY domain in primates, ﬁve other primate TRIM5α SPRY
domain sequences were used: human (NCBI accession number
AK027593), african green monkey (AB210050), cynomolgus monkey
(AB210052), rhesus monkey (AY523632) and sooty mangabey
(AY710303, EF551344). Alignment of the baboon and other primate
SPRY domain sequences to the three templates was obtained with the
T-Coffee method (Notredame et al., 2000). Two additional methods
(Edgar, 2004, Thompson et al., 1994) have also been used to generate
multiple sequence alignments. Comparison of the alignments gener-
ated by the three methods revealed only minor differences. In
particular, the three alignments differ by a shift of two to three
positions in the placement of four insertions in the primate SPRY
domain relative to the template sequences. This indicates that the
alignment is reliable except in the regions of these four insertions since
other parts of the sequences are aligned in the same manner
independently of the method used. The model was built using
Modeller 9v4 (Eswar et al., 2006; http://salilab.org/modeler) and
visualized with PyMol v1.0r2 (DeLano WL, http://www.pymol.org).
168 K. Kono et al. / Virology 388 (2009) 160–168TRIM5α cDNA sequences
TRIM5α cDNA sequences for baboon (AY843505), orangutan
(DQ437601), and gorilla (DQ4307600) were obtained from the
GenBank database.
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